Genotype-Guided Antidepressant Prescribing for Patients With Depression

Does pharmacogenetic-guided prescribing of selective serotonin reuptake inhibitors (SSRIs) improve treatment response in patients with depression?In this randomized clinical trial of 1460 adults and children, analyses were conducted among those with an actionable drug metabolism phenotype. In this group, genotype-guided management using validated, publicly available guidelines for SSRI prescribing did not improve depression symptom scores at 3 months compared with usual care, but remission rates between 3 and 6 months were higher.The higher remission rates observed at 6 months in this trial suggest a potential longer-term benefit that warrants further study.

Corresponding Author: Josh F. Peterson, MD, MPH, Department of Biomedical Informatics, Vanderbilt University Medical Center, 2525 West End Ave, Ste 1500, Nashville, TN 37203 (josh.peterson@vumc.org).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.